AstraZeneca’s CORSAR Study: Unveiling Severe Asthma Insights in Russia

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca is currently conducting a study titled ‘Clinical and Demographic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR).’ The study aims to gather comprehensive epidemiological data on patients with uncontrolled severe asthma (SA) in Russia. This observational, multicenter, cross-sectional study will involve 5,000 adult patients across 50 outpatient centers in various Russian regions, focusing on understanding the clinical and demographic characteristics of these patients.

The study does not involve any new interventions but instead observes patients receiving standard care, excluding biologics. The goal is to analyze treatment patterns and clinical outcomes in real-world settings, providing valuable insights into the management of severe asthma in Russia.

The study is observational in nature, with a cross-sectional design. It involves a single visit to collect demographic and clinical data from participants. The primary purpose is to document and analyze the characteristics of severe asthma in different regions of Russia.

Key dates for the study include a start date of January 29, 2024, and the latest update on July 18, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data collection and analysis.

This study could have significant market implications for AstraZeneca, potentially influencing their stock performance as it enhances understanding of severe asthma treatment in a large and diverse population. The findings may also impact investor sentiment by highlighting AstraZeneca’s commitment to addressing unmet medical needs in asthma care.

The study is ongoing, with further details available on the ClinicalTrials portal.